Neuropeptide Y

What is Neuropeptide Y?

Neuropeptide Y (NPY) is a 36-amino-acid endogenous peptide, discovered in 1982 by Kazuhiko Tatemoto at the Karolinska Institute, and one of the most abundant neuropeptides in the mammalian brain. It is the defining member of the NPY family — together with peptide YY (PYY) and pancreatic polypeptide (PP) — all of which share a characteristic PP-fold structure and signal through a family of five G-protein-coupled receptors (Y1, Y2, Y4, Y5, and the human pseudogene Y6). In the brain, NPY is best known as the master orexigenic signal: NPY-expressing neurons in the arcuate nucleus of the hypothalamus, co-releasing with agouti-related peptide (AgRP), fire in the fasted state and drive hunger, counter-regulated by anorexigenic POMC neurons and suppressed by leptin and insulin. Beyond feeding, NPY plays major roles in stress buffering and anxiolysis (chiefly via Y1 receptors in the amygdala), cardiovascular regulation (Y1-mediated sympathetic vasoconstriction at high adrenergic drive), and circadian physiology. NPY is not a therapeutic product: it is endogenous biology that anchors some of the most important neuroendocrine circuits in the body.

What Neuropeptide Y Is Investigated For

NPY is a physiology topic, not a peptide you buy. Its importance sits in three well-established endogenous roles. First, it is the central nervous system's primary hunger signal — the Clark 1984 Endocrinology paper showing that intracerebroventricular NPY drives feeding in rats, and the subsequent decades of work on NPY/AgRP neurons in the arcuate nucleus, established NPY as the orexigenic counterweight to POMC and leptin. Second, it is an endogenous anxiolytic: intra-amygdala NPY reduces anxiety-like behavior in rodents through Y1-receptor signaling (Heilig and colleagues, 1990s), and in human studies lower plasma and cerebrospinal-fluid NPY concentrations track with combat-related PTSD and poorer stress resilience (Morgan, Rasmusson, and colleagues). Third, it is a sympathetic co-transmitter that contributes to Y1-receptor-mediated vasoconstriction at high sympathetic drive. The therapeutic angle most consumers encounter is the opposite of direct supplementation: pharmaceutical development has pursued Y1 and Y5 receptor antagonists as anti-obesity drugs, and despite strong preclinical rationale, clinical results have been disappointing — Merck's Y5 antagonist MK-0557 produced only statistically-but-not-clinically-meaningful weight loss over 52 weeks, and the class has not yielded an approved drug. The honest framing is that NPY is foundational neuroendocrine biology that explains a great deal about hunger, stress, and the limits of appetite-suppressant pharmacology — not a compound you can or should self-administer.

History & Discovery

Neuropeptide Y was isolated and sequenced in 1982 by Kazuhiko Tatemoto, working in Viktor Mutt's laboratory at the Karolinska Institute in Stockholm — the same laboratory and the same researcher who, earlier that year, had characterized peptide YY (PYY) from porcine intestine using a chemical method that detected peptides with C-terminal tyrosine amides. Applying the same approach to porcine brain tissue yielded a closely related 36-amino-acid peptide with roughly 70% sequence identity to PYY and 50% to pancreatic polypeptide. Tatemoto named it 'neuropeptide Y' — the 'Y' referencing both its brain (neuro-) origin and the tyrosine (single-letter code Y) residues that bracket the molecule. The two 1982 papers — the Nature paper announcing the isolation and the PNAS paper presenting the complete amino acid sequence — founded what is now called the NPY peptide family. The functional story unfolded over the following decade. In 1984, Clark, Kalra, Crowley, and Kalra published in Endocrinology that intracerebroventricular NPY administration in rats produced dose-dependent increases in food intake, establishing NPY as an orexigenic neuropeptide. Further work localized the effect to hypothalamic sites, particularly the paraventricular nucleus. The discovery that a discrete population of arcuate-nucleus neurons co-expressed NPY and agouti-related peptide (AgRP), fired during fasting, and provided the opposing signal to the anorexigenic POMC population, emerged through the 1990s and 2000s and made NPY/AgRP neurons one of the most intensively studied circuits in neuroscience. In parallel, Markus Heilig and colleagues developed the anxiolytic story: intracerebral NPY in rats reduced anxiety-like behavior in established behavioral paradigms, and amygdala Y1 receptors were shown by antisense and pharmacological approaches to be the critical substrate. Human translational work beginning in the 1990s, led by Charles Morgan, Ann Rasmusson, and collaborators at Yale and the US military, showed that lower plasma and cerebrospinal-fluid NPY concentrations correlated with combat-related PTSD and poorer stress resilience, suggesting NPY as a candidate biomarker of stress tolerance. Receptor pharmacology was worked out through the 1990s, identifying the five mammalian Y receptors (Y1, Y2, Y4, Y5, Y6 — the last a pseudogene in humans). The obesity-drug hypothesis that followed — that blocking hypothalamic Y1 or Y5 receptors would suppress appetite — drove a generation of medicinal chemistry at multiple pharmaceutical companies. The two compounds that reached the furthest in clinical development, Merck's Y5-selective MK-0557 and Shionogi's velneperit (S-2367), were both tolerated but produced only statistically-significant, not clinically-meaningful, weight loss in Phase 2 trials and were discontinued. The clinical verdict on Y-receptor antagonism for obesity has since been overshadowed by the rise of GLP-1-based therapeutics, and NPY remains important as endogenous biology rather than as a drug-development target.

How It Works

NPY is one of the brain's most abundant signaling peptides. Neurons that make it in the arcuate nucleus of the hypothalamus fire when you're hungry or underfed, and their output is the core 'eat now' signal your brain sends — counter-balanced by POMC neurons ('you're full') and suppressed by leptin from fat tissue. NPY also acts in the amygdala to dampen anxiety, and in sympathetic nerves to help constrict blood vessels during stress.

NPY is a 36-amino-acid peptide with a characteristic PP-fold hairpin structure, expressed throughout the central and peripheral nervous systems, with the highest brain concentrations in the hypothalamic arcuate nucleus, paraventricular nucleus, amygdala, and nucleus accumbens. It signals through five G-protein-coupled receptors in mammals — Y1, Y2, Y4, Y5, and Y6 (a pseudogene in humans and most primates) — all coupling predominantly to Gi/o and inhibiting adenylate cyclase, with variable effects on calcium and potassium channels. In the arcuate nucleus, NPY is co-expressed with AgRP and GABA in a discrete neuronal population (commonly called NPY/AgRP neurons) that sits at the center of the melanocortin system. These neurons fire in the fasted state, are directly activated by ghrelin and inhibited by leptin, insulin, and PYY(3-36) (the latter via presynaptic Y2 autoreceptors), and project to the paraventricular nucleus and other downstream feeding circuits where NPY released at Y1 and Y5 receptors drives food-seeking and food intake. Chemogenetic activation of these neurons is sufficient to produce intense feeding even in sated animals; their ablation in adult mice produces acute starvation. Outside the feeding circuit, NPY in the central nucleus of the amygdala acts on Y1 receptors to produce anxiolytic effects — Heilig and colleagues demonstrated that intracerebral NPY reduces anxiety-like behavior in rodents and that Y1 antisense knockdown in the amygdala abolishes the effect. In the periphery, NPY is co-released with norepinephrine from sympathetic nerve terminals, particularly during high-frequency or high-intensity sympathetic activation, and produces vasoconstriction through vascular smooth-muscle Y1 receptors; it also modulates cardiac function and angiogenesis. The short plasma half-life of NPY (minutes), its primarily paracrine/synaptic mode of action, and the complexity of tissue-specific receptor distribution are the main reasons NPY itself has never been developed as a systemic therapeutic.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Neuropeptide Y:

• 01Why Y5 and Y1 receptor antagonism has consistently underperformed in human obesity trials despite strong preclinical rationale — whether this reflects redundancy among Y receptors, compensatory circuit plasticity, or species differences in NPY circuit architecture.
• 02Whether selectively targeting specific NPY-expressing neuronal populations (e.g. arcuate NPY/AgRP neurons) without systemic NPY receptor blockade could separate efficacy from tolerability in obesity pharmacotherapy.
• 03Whether the plasma and CSF NPY deficits observed in PTSD are causally contributing to the disorder or represent a downstream consequence of chronic stress-axis dysregulation.
• 04Whether intranasal or other CNS-targeted NPY delivery could produce meaningful anxiolytic or PTSD-protective effects in humans — small pilot studies exist; definitive trials do not.
• 05The functional significance of the Y6 receptor in humans, given that it is a pseudogene in most primates but functional in rodents — and whether this explains species differences in NPY pharmacology that have complicated drug translation.
• 06The interaction between NPY signaling and modern GLP-1-class obesity drugs — whether chronic GLP-1 agonism engages or bypasses hypothalamic NPY circuits, and whether combined targeting could add benefit.
• 07The role of peripheral (sympathetic co-transmitter) NPY in long-term cardiovascular risk — observational associations between NPY polymorphisms and cardiovascular outcomes exist, but causal mechanisms remain unsettled.

Forms & Administration

NPY is not available as an approved therapeutic in any form and is not administered clinically. Research studies in humans have used intravenous or intranasal infusion of synthetic NPY under IND protocols — there is no consumer route of administration. Pharmaceutical development has focused on small-molecule Y1 and Y5 receptor antagonists (oral compounds such as MK-0557 and velneperit) rather than on NPY itself. Compounded NPY is not a meaningful clinical product and has no validated indication.

Common Questions

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions